[Progress in the field of drug development. 18].
Délenk-Heydenreich
K
K
Henkler
G
G
Keller
U
U
Klotzbach
M
M
Koch
H
H
Müller
W
W
Richter
J
J
D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000903:Antibiotics, Antineoplastic; D000959:Antihypertensive Agents; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D002317:Cardiovascular Agents; D006801:Humans; D007004:Hypoglycemic Agents; D007328:Insulin; D007372:Interferons; D008935:Mitoguazone; D009294:Narcotics; D010600:Pharmacology; D010879:Piperazines; D011954:Receptors, Dopamine / Q000187:drug effects; D012176:Retinoids
D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000903:Antibiotics, Antineoplastic; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D002317:Cardiovascular Agents; D007004:Hypoglycemic Agents; D007328:Insulin; D009294:Narcotics; D010879:Piperazines; D011954:Receptors, Dopamine; D012176:Retinoids; D007372:Interferons; D008935:Mitoguazone
Fortschritte auf dem Gebiet der Arzneimittelentwicklung. Teil 18.